GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gencurix 229000.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in KRW, from our data supplier.

FY2025

Revenue

₩7.55bn

FY2016FY2025

Net income

−₩7.39bn

FY2016FY2025

Free cash flow

−₩6.69bn

FY2016FY2025

Shareholders' equity

₩16.37bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue₩7.55bn₩5.13bn₩2.60bn₩2.56bn₩3.05bn₩1.57bn₩136.6m₩252.3m₩6.7m₩585.8m
Research and development₩2.97bn₩4.22bn₩4.53bn₩4.18bn₩3.47bn₩3.15bn₩2.20bn———
Operating income—−₩3.44bn−₩19.74bn−₩14.15bn−₩12.47bn−₩9.27bn−₩6.56bn−₩5.71bn−₩6.33bn−₩8.16bn
Net income−₩7.39bn−₩3.63bn−₩19.26bn−₩24.60bn−₩34.67bn₩33.11bn−₩9.16bn−₩5.72bn−₩6.82bn−₩9.06bn
Diluted earnings per share-315.27-229.48-1,400.81-3,352.65-4,805.025,174.08-1,699.00-875.23-1,148.46-1,614.61

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets₩32.11bn₩30.04bn₩33.50bn₩37.24bn₩55.29bn₩63.98bn₩2.39bn₩10.14bn₩7.36bn₩9.23bn
Cash and short-term investments—₩4.54bn₩11.27bn₩5.86bn₩21.96bn₩5.63bn₩561.9m₩7.23bn₩4.52bn₩6.36bn
Total liabilities₩15.74bn₩15.15bn₩21.50bn₩30.76bn₩24.30bn₩10.60bn₩2.23bn₩943.8m₩955.8m₩1.03bn
Debt₩53.8m₩1.36bn₩4.69bn₩4.00bn₩237.9m₩1.46bn₩859.4m₩550.0m₩550.0m₩550.0m
Shareholders' equity₩16.37bn₩14.90bn₩13.78bn₩6.48bn₩30.99bn₩53.38bn₩155.2m₩9.20bn₩6.41bn₩8.20bn
Shares outstanding23m16m14m7m7m6m5m7m6m6m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−₩6.24bn−₩7.17bn−₩10.86bn−₩10.45bn−₩8.37bn−₩13.59bn−₩5.22bn−₩5.03bn−₩5.41bn−₩5.98bn
Capital spending−₩448.7m−₩761.7m−₩2.18bn−₩13.05bn−₩1.08bn−₩1.12bn−₩814.8m−₩621.8m−₩220.1m−₩677.2m
Free cash flow−₩6.69bn−₩7.93bn−₩13.04bn−₩23.50bn−₩9.44bn−₩14.71bn−₩6.04bn−₩5.66bn−₩5.63bn−₩6.66bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue₩2.99bn₩2.10bn₩2.11bn₩1.73bn₩2.00bn₩1.71bn₩2.32bn₩1.44bn
Operating income−₩701.6m—−₩1.47bn——−₩1.82bn₩4.57bn−₩1.84bn
Net income−₩1.29bn−₩2.37bn−₩1.82bn−₩2.03bn−₩1.54bn−₩2.00bn₩5.53bn−₩1.87bn
Diluted earnings per share-54.86-101.19-77.56-126.18-95.37-126.46349.86-122.48
Cash from operations₩295.0m−₩1.31bn−₩1.33bn−₩1.28bn−₩2.34bn−₩1.29bn−₩7.17bn−₩5.75bn
Capital spending−₩21.0m−₩191.0m−₩87.0m−₩70.0m−₩196.0m−₩93.0m−₩761.0m−₩493.0m
Free cash flow₩274.0m−₩1.50bn−₩1.41bn−₩1.35bn−₩2.53bn−₩1.38bn−₩7.93bn−₩6.24bn
Total assets₩31.17bn₩31.09bn₩32.11bn₩24.88bn₩26.90bn₩27.60bn₩30.04bn₩24.32bn
Cash and short-term investments—————₩2.38bn₩4.54bn₩4.68bn
Debt₩59.2m₩56.5m₩53.8m—₩1.12bn₩1.33bn₩1.36bn₩1.45bn
Shareholders' equity₩12.61bn₩13.99bn₩16.37bn₩9.20bn₩11.47bn₩12.62bn₩14.90bn₩10.70bn

Financial ratios

Data as of 19 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Operating margin—-67.0%-759.3%-553.0%-409.2%-589.5%-4801.5%
Net margin-97.9%-70.6%-740.7%-961.0%-1137.9%2106.1%—
Return on equity-45.1%-24.3%-139.8%-379.9%-111.9%62.0%—
Return on assets-23.0%-12.1%-57.5%-66.1%-62.7%51.7%—
Revenue growth47.0%97.4%1.6%-16.0%93.8%1050.6%—
Earnings growth103.7%-81.2%-21.7%-29.1%-204.7%-461.4%—
Current ratio1.12x0.68x0.87x0.31x1.02x1.30x—
Debt to equity0.00x0.08x0.34x0.59x0.00x0.02x—
Equity ratio51.0%49.6%41.1%17.4%56.1%83.4%—
Interest coverage—-4.49x-24.35x-29.60x-44.81x-40.20x-86.20x
R&D as a share of sales39.4%82.2%174.2%163.4%114.0%200.6%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue43.4%36.9%29.3%
Net income-33.0%—6.4%

Average margins

Over each period

1 year3 years5 years10 years
Net margin-86.8%-307.5%-251.2%-379.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-4.9-8.6-4.4-1.9-3.42.9-8.8-21.9-11.8-9.3
Price to sales4.86.132.918.138.661.2—496.0—144.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 127-for-113 split · 7 Mar 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.